North Dakota Medicaid spending on GLP-1 drugs

How much did North Dakota Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $3.6 million for GLP-1 drugs paid through North Dakota Medicaid in 2025, across at least 5,852 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 57 rows of 100, so these figures are floors.

Pharmacies were reimbursed at least $2.2 million for GLP-1 drugs paid through North Dakota Medicaid in 2026 (quarter 1 only, as posted so far), across at least 2,335 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 15 rows of 26, so these figures are floors.

By year and ingredient

2020at least $51,628No data$1,902,198at least $9,329at least $635,149No dataat least $2,598,304
2021at least $225,341No data$3,046,820at least $88,873at least $181,541No dataat least $3,542,574
2022at least $202,542Suppressedat least $4,209,616at least $367,191SuppressedNo dataat least $4,779,349
2023at least $181,027Suppressedat least $5,382,938$502,322SuppressedNo dataat least $6,066,287
2024at least $348,723Suppressedat least $3,430,771at least $318,676SuppressedNo dataat least $4,098,169
2025at least $1,590,804at least $70,880at least $1,943,466SuppressedNo dataSuppressedat least $3,605,150
2026 (Q1)at least $1,800,391at least $47,641at least $343,928SuppressedNo dataSuppressedat least $2,191,959

By product, 2025

Ozempic$1,580,0401,6160 of 12
Rybelsusat least $10,763at least 1110 of 11
WegovySuppressedSuppressed8 of 8
Mounjaroat least $70,880at least 6719 of 24
Liraglutide (generic name listing)at least $1,059,875at least 2,8153 of 20
Victoza$883,5911,3430 of 8
TrulicitySuppressedSuppressed15 of 15
XultophySuppressedSuppressed2 of 2

By quarter, 2025

Q1 2025at least $669,855at least 96414 of 19
Q2 2025at least $708,639at least 1,37917 of 27
Q3 2025at least $842,128at least 1,63514 of 27
Q4 2025at least $1,384,529at least 1,87412 of 27

By quarter, 2026 (posted so far)

Q1 2026at least $2,191,959at least 2,33515 of 26

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.